Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Midazolam + remifentanil moderate sedation dosing study for gastroscopy
ChiCTR1900023868Phase 4Recruiting
- Sponsor
- Beijing Friendship Hospital
- Start
- Jun 2019
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of midazolam and remifentanil in gastrointestinal conditions, sponsored by Beijing Friendship Hospital. Primary endpoint: Observer's Assessment of Alertness/Sedation Scale. Started Jun 2019; status: recruiting.
02
Drugs
midazolamremifentanil
03
Conditions
gastrointestinal conditions
Beyond the preview
Go deeper on ChiCTR1900023868.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1900023868.